Cover Image

Effect of Nebivolol on serum lipid levels in hypertensive Male Sprague-Dawley (SD) rat models- A Pilot Study

HEMA P PALANIAPPAN

Abstract


AbstractAims and objectives To evaluate the effect of Nebivolol on serum lipids in hypertensive male Sprague-Dawley (SD) rat model. Materials and Methods  Nebivolol is a 3rd generation beta 1 selective blocker with  vasodilating property. The effect of nebivolol was studied in male hypertensive Sprague Dawley rats. Hypertension was induced by providing the rats with drinking water containing 20 fructose daily for 6 weeks. This high dose of fructose produced hypertension and dyslipidemia after 6 weeks. Periodic    evaluation of blood pressure was done using non-invasive blood pressure (NIBP) apparatus. After hypertension was induced, the rats were subjected to treatment with nebivolol 10 mgkg for 4 weeks. The blood pressure and lipid profile for each animal were noted before the start of the study, after induction of   hypertension and after treatment with nebivolol and the values were compared using paired t test. Results The oral  administration of nebivolol at a dose of 10mgkg showed   significant reduction in total plasma cholesterol, low-density lipoprotein level and triglycerides respectively after 4 weeks of treatment.ConclusionThe present study shows that nebivolol when used as antihypertensive also alters the lipid profile    favorably.

 

 


Full Text:

PDF

References


Wong ND, Lopez V, Tang S, Williams GR. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol. 2006; 98:204-8.

Acharya VN. Diabetic and hypertensive nephropathy in India. JAPI March 2011 vol59

Balakumar P, Jindal S, Shah DI, Singh M; Experimental models for vascular endothelial dysfunction; Trends Med Res, 2010(2):12-20

Samanta A, Burden AC, Feehally J, et al. Diabetic renal disease: differences between Asian and white patients. Br Med J 1986; 293:366-67.

Robert W. Nebivolol-a novel beta blocker with nitric oxide-induced vasodilatation. Androscoggin cardiology associates. Vascular health and risk management 2006;2(3) 303-308

de Groot AA, Mathy MJ, van Zwieten PA, Peters SL; Involvement of the beta3 adrenoceptor in nebivolol-induced vasorelaxation in the rat aorta; J Cardiovasc pharmacol.2003 Aug; 42(2):232-6

Schmidt AC, Graf C, Brixius K, Scholze J. Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: the YESTONO study. Clinical Drug Investig 2007; 27 12):841-9.

Van Nueten L, Schelling A, Vertommen C, Dupont AG, Robertson JI: Nebivolol vs enalapril in the treatment of essential hypertension: a double-blind randomised trial. J Hum Hypertens, 1997, 11, 813–819.

Dorota Gorska, Michal Dudarewicz, Elzbieta Czarnecka, Dariusz Andrzejczak: Does nebivolol influence serum concentrations of proinflammatory cytokines in hypertensive (SHR) and normotensive (WKY) rats 2010; 62:86-94.

Motoyama CS, Pinto MJ, Lira FS, Ridbeiro EB, Do Nascimento CM and Oyama LM, “Gum Guar fiber associated with fructose reduces serum triacylglycerol but did not improve the golucose tolerance in rats”Diabetology and Metabolic Syndrome, 2010 Vol.2, article61:2-8

I Shun Hwang, Helen Ho,et al. Fructose induced insulin resistance and hypertension in rats; journal of hypertension. American heart association.palo; 10(5):512-6.

Barone S, Fussell SL, Singh AK et al., “Slc2a5 (Glut5) is essential for the absorption of fructose in the intestine and generation of fructose-induced hypertension,” Journal of Biological Chemistry, vol. 284, no. 8, pp. 5056–5066, 2009.

de Groot AA, Mathy M-J, van Zwieten PA, Peters SLM. Vasodilator effects of nebivolol in a rat model of hypertension and a rabbit model of congestive heart failure. J Cardiovasc Pharmacol, 2007; 50: 56–60.

Ladage D, Brixius K, Hoyer H, Steingen C, Wesseling A, Malan D, Bloch Wet al.: Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells. Clin Exp Pharmacol Physiol, 2006, 33, 720–724

Ignarro LJ: Experimental evidences of nitric oxide dependent vasodilatory activity of nebivolol, a third generation beta-blocker. Blood Press Suppl, 2004, 1, 2–16.

Wolf SC, Sauter G, Preyer M, Poerner T, Kempf VA,Risler T, Brehm BR: Influence of Nebivolol and metoprolol on inflammatory mediators in human coronary endothelial or smooth muscle cells. Effects on neointima formation after balloon denudation in carotid arteries of rats treated with nebivolol. Cell Physiol Biochem, 2007, 19, 129–136.

Pasini AF, Garbin U, Nava MC, Stranieri C, Davoli A, Sawamura T. nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens. 2005; 23:589–96.

Samie R Jaffrey; Nitric Oxide. In Basic and Clinical Pharmacology, 12th edition; Mc-Graw Hill; New York; 2012

Badar VA, Hiware SK, Shrivastava MP, Thawani VR, Hardas MM; Comparison of nebivolol and atenolol on blood pressure, blood sugar, and lipid profile in patients of essential hypertension; Indian J Pharmacol. 2011 Jul; 43(4):437-40.

Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G; Noradrenergic transmission. In Rang and Dale’s Pharmacology, 7th edn; Elsevier Churchill Livingstone; London; 2012.

Duncan RE, Ahamadian M,Jaworski K,Sarkadi-Nagy E,Sul HS.Regulation of lipolysis in adipocytes.Annu Rev Nutr.2007;27: 79-101.

Guo YQ, Li YF, Wang ZH.; Effects of -adrenoceptor on scavenger receptor class B type 1 and its signal transduction pathway in apolipoprotein E knockout mice; Eur J Pharmacol. 2013 Aug 15; 714(1-3):295-302.

Subramanian.G, Rama Mohan.P,Ramalingam.K. Prevalence of cardiovascular risk factors in rural population of Nellore district IJAPBS April-June -2012; 1(2):30-33.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

An Initiative of The Tamil Nadu Dr M.G.R. Medical University